CRISPR-Cas9 technology introduced a S236X mutation, which is similar to the R237X mutation identified in Weill-Marchesani syndrome patients, and results in a premature stop codon. The mutation site is immediately after the propeptide at the start of the catalytic domain. RT-PCR confirmed a 106 bp deletion. (J:266801)